Literature DB >> 2198052

Adverse reactions and interactions with theophylline.

M H Skinner1.   

Abstract

Despite the trend towards newer therapeutic agents, theophylline continues to play a major role in the treatment of reversible airway obstruction. Clinical use of the drug is complicated by a relatively narrow therapeutic range and a large pharmacokinetic variability between patients. Generally, however, theophylline toxicity is foreseeable and preventable. Most cases can be attributed to either inadvertent or intentional overdosing of the drug. Age, disease state and drug interactions are other factors which may contribute to its toxicity. Nausea, vomiting and tachycardia are common signs of mild theophylline toxicity; seizures, ventricular arrhythmias and hypotension are life-threatening manifestations of severe toxicity which may respond poorly to standard therapy. Although serum theophylline concentration correlates with toxicity in a general fashion, life-threatening adverse reactions are not readily predictable from the drug concentration alone. Treatment of theophylline toxicity primarily involves supportive care along with gastric lavage and administration of activated charcoal to facilitate drug removal. The early use of haemoperfusion may be life-saving in cases of severe toxicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2198052     DOI: 10.2165/00002018-199005040-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  117 in total

1.  Theophylline-induced lomustine toxicity.

Authors:  P M Zeltzer; S A Feig
Journal:  Lancet       Date:  1979-11-03       Impact factor: 79.321

2.  Theophylline and serum electrolytes.

Authors:  F A Zantvoort; F H Derkx; F Boomsma; P J Roos; M A Schalekamp
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

3.  Enoxacin raises plasma theophylline concentrations.

Authors:  W J Wijnands; C L van Herwaarden; T B Vree
Journal:  Lancet       Date:  1984-07-14       Impact factor: 79.321

4.  Combined use of beta-adrenergic agonists and methyl xanthines.

Authors:  R A Nicklas; V E Whitehurst; R F Donohoe
Journal:  N Engl J Med       Date:  1982-08-26       Impact factor: 91.245

5.  Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline.

Authors:  J J Coleman; W M Vollmer; A F Barker; G E Schultz; A S Buist
Journal:  Chest       Date:  1986-07       Impact factor: 9.410

6.  Oral activated charcoal to enhance theophylline elimination in an acute overdose.

Authors:  P Gal; A Miller; J D McCue
Journal:  JAMA       Date:  1984-06-15       Impact factor: 56.272

Review 7.  Effects of enprofylline and theophylline may show the role of adenosine.

Authors:  C G Persson; K E Andersson; G Kjellin
Journal:  Life Sci       Date:  1986-03-24       Impact factor: 5.037

8.  Inhibition of theophylline metabolism by long-term allopurinol administration.

Authors:  R L Manfredi; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

9.  Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline.

Authors:  G Ho; M G Tierney; R E Dales
Journal:  Clin Pharmacol Ther       Date:  1988-07       Impact factor: 6.875

Review 10.  Food interactions with sustained-release theophylline preparations. A review.

Authors:  J H Jonkman
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

View more
  2 in total

1.  Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics.

Authors:  F Sörgel; G Mahr; G R Granneman; U Stephan; P Nickel; P Muth
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

Review 2.  Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review.

Authors:  Elnaz Khani; Sajad Khiali; Samineh Beheshtirouy; Taher Entezari-Maleki
Journal:  Eur J Pharmacol       Date:  2021-10-19       Impact factor: 4.432

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.